Redmile Group LLC 13D and 13G filings for Fate Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-12-26 9:00 pm Purchase |
2024-12-20 | 13D | Fate Therapeutics, Inc. FATE |
Redmile Group LLC | 17,816,634 14.900% |
197,539 (+1.12%) |
Filing |
| 2024-03-25 5:15 pm Purchase |
2024-03-21 | 13D | Fate Therapeutics, Inc. FATE |
Redmile Group LLC | 17,619,095 14.900% |
2,569,256 (+17.07%) |
Filing |
| 2023-12-28 4:53 pm Sale |
2023-12-26 | 13D | Fate Therapeutics, Inc. FATE |
Redmile Group LLC | 15,049,839 14.900% |
-21,257 (-0.14%) |
Filing |
| 2023-04-19 5:15 pm Purchase |
2023-04-13 | 13D | Fate Therapeutics, Inc. FATE |
Redmile Group LLC | 15,071,096 14.900% |
2,077,208 (+15.99%) |
Filing |
| 2021-01-12 4:18 pm Purchase |
2021-01-08 | 13D | Fate Therapeutics, Inc. FATE |
Redmile Group LLC | 12,993,888 14.100% |
332,152 (+2.62%) |
Filing |
| 2020-06-17 8:26 pm Purchase |
2020-06-11 | 13D | Fate Therapeutics, Inc. FATE |
Redmile Group LLC | 12,661,736 14.900% |
1,434,928 (+12.78%) |
Filing |